{"id":"W2890273388","doi":"10.1200/jco.2017.35.15_suppl.8027","title":"Pomalidomide (POM) + low-dose dexamethasone (LoDEX) after lenalidomide (LEN)-based second-line (2L) treatment (Tx) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): Analysis of progression-free survival (PFS) by level of disease control.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Baker Hughes (Canada); McGill University Health Centre; Vancouver General Hospital","funders":"","keywords":"Medicine; Pomalidomide; Lenalidomide; Internal medicine; Daratumumab; Progressive disease; Clinical endpoint; Multiple myeloma; Cohort; Population; Neutropenia; Bortezomib; Refractory (planetary science); Surgery; Dexamethasone; Oncology; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009198902,0.0002959202,0.0005365729,0.0002639926,0.0001863306,0.0005338989,0.0002726358,0.0002728033,0.001381406],"category_scores_gemma":[0.0008603119,0.0001434496,0.000583862,0.0002901083,0.0001923586,0.0003511432,0.0003025797,0.0006619122,0.0002175735],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006551672,"about_ca_system_score_gemma":0.0004616651,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008250783,"about_ca_topic_score_gemma":0.001863623,"domain_scores_codex":[0.9996711,0.0001191997,0.00002425071,0.00008507699,0.00005242636,0.00004798367],"domain_scores_gemma":[0.9993185,0.000150543,0.0002689643,0.00003887371,0.00002516063,0.0001979851],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1980817,0.004424772,0.6430557,0.0003689285,0.001946368,0.0003321562,0.0002858135,0.00309078,0.01306495,0.0001647223,0.002425197,0.132759],"study_design_scores_gemma":[0.01401725,0.1652038,0.8037416,0.00007999913,0.001300147,0.001125688,0.0001378057,0.00487669,0.004940123,0.0001848019,0.004363658,0.00002847119],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9982238,0.0007695236,0.000147307,0.00004833995,0.000006546582,0.00005396127,0.0004142811,0.00001088545,0.0003253732],"genre_scores_gemma":[0.9983363,0.0002158268,0.0002028567,0.00008392557,0.00001738147,0.00004234209,0.0007753483,0.000003132798,0.0003230136],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001381406,"threshold_uncertainty_score":0.004864931,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1170935448345952,"score_gpt":0.4371151103498414,"score_spread":0.3200215655152462,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}